ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

Characterization of thrombogenic effects of platelet tyrosine phosphatase SHP2 inhibition using the allosteric inhibitor SHP099

1School for Cardiovascular Diseases (CARIM), Maastricht University, 6200 MD Maastricht, The Netherlands, Maastricht, Limburg, Netherlands, 2Platelet Proteomics Group, Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain, Santiago de Compostela, Galicia, Spain, 3Department of Biochemistry, CARIM, Maastricht University, 6200 MD Maastricht, The Netherlands, Maastricht, Limburg, Netherlands, 4Department of Anesthesiology and Intensive Care Medicine, Clinical University Hospital of Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Galicia, Spain, 5Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University; Thrombosis Expertise Centre, Heart and Vascular Centre, Maastricht University Medical Centre, Maastricht, The Netherlands, Maastricht, Limburg, Netherlands, 6Department of Biochemistry, CARIM, Maastricht University, Maastricht, the Netherlands; Synapse Research Institute Maastricht, The Netherlands, Maastricht, Limburg, Netherlands

Abstract Number: PB0396

Meeting: ISTH 2022 Congress

Theme: Platelets and Megakaryocytes » Platelet Signaling

Background: Protein tyrosine phosphatase SHP2 is a known regulator of platelet signal transduction potentially suppressing GPVI-induced activation. Currently, there are clinical trials with derivatives of the allosteric drug SHP099, which inhibits SHP2, as therapy for solid cancers. Human mutations of SHP2 gene, PTPN11, have been described to be linked to a variety of diseases.

Aims: Assessment of the potential thrombogenic effect of drug-induced SHP2 inhibition.

Methods: Washed human platelets were incubated with SHP099 and stimulated with the GPVI agonists collagen-related peptide (CRP) or collagen for aggregation and flow cytometric measurements. Drug effects of shear-dependent thrombus and fibrin formation were determined using whole-blood microfluidics over low and high collagen concentrations. In all assays, effects of co-inhibition of P2Y12 ADP receptor blocker were examined. Thromboelastography was used to evaluate the effect on clot formation.

Results: Pharmacological inhibition of SHP2 in washed platelets did not alter GPVI-dependent platelet aggregation regardless of the GPVI agonist used and P2Y12 inhibition. However, inhibition of SHP2 triggered faster integrin GPIIbIIIa opening, when assesed after GPVI activation. Moreover, in whole blood microfluidic assays, the drug enhanced the buildup of thrombus volume on collagen surfaces. When limiting the thrombus buildup by P2Y12 inhibition, this enhancement was abolished. In the presence of tissue factor and coagulation, the drug significantly enhanced thrombus volume, size, and contraction as well as fibrin formation. In thromboelastography, tissue factor-induced blood clotting profiles were enhanced with tranexamic acid, preventing fibrinolysis.

Conclusion(s): The thrombogenic effect of SHP2 inhibition is not confined to early GPVI activation and requires the presence of shear and/or coagulation.

To cite this abstract in AMA style:

Fernández de la Fuente D, Hermida-Nogueira L, Huang J, Veiras S, Kuijpers M, Heemskerk J, García Á. Characterization of thrombogenic effects of platelet tyrosine phosphatase SHP2 inhibition using the allosteric inhibitor SHP099 [abstract]. https://abstracts.isth.org/abstract/characterization-of-thrombogenic-effects-of-platelet-tyrosine-phosphatase-shp2-inhibition-using-the-allosteric-inhibitor-shp099/. Accessed September 27, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/characterization-of-thrombogenic-effects-of-platelet-tyrosine-phosphatase-shp2-inhibition-using-the-allosteric-inhibitor-shp099/